Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Clinical utility of β-blockers for primary and secondary prevention of coronary artery disease.

Calhoun M, Cross LB, Cooper-DeHoff RM.

Expert Rev Cardiovasc Ther. 2013 Mar;11(3):289-91. doi: 10.1586/erc.13.16.

PMID:
23469908
2.

β-blocker therapy after acute myocardial infarction.

Tabrizchi R.

Expert Rev Cardiovasc Ther. 2013 Mar;11(3):293-6. doi: 10.1586/erc.13.15.

PMID:
23469909
3.
5.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

6.

Pharmacologic therapies after myocardial infarction.

Rapaport E, Gheorghiade M.

Am J Med. 1996 Oct 8;101(4A):4A61S-69S; discussion 4A69S-70S. Review.

PMID:
8900339
7.

Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.

Giorgberidze I, Saksena S, Krol RB, Munsif AN, Kolettis T, Mathew P, Varanasi S, Prakash A, Delfaut P, Lewis CB.

Am J Cardiol. 1997 Sep 11;80(5B):3F-9F.

PMID:
9291444
8.

Optimising the use of beta-adrenoceptor antagonists in coronary artery disease.

Ellison KE, Gandhi G.

Drugs. 2005;65(6):787-97. Review.

PMID:
15819591
9.

Secondary prevention after myocardial infarction: in favor of beta-blockers.

Lévy S.

J Cardiovasc Pharmacol. 1990;16 Suppl 6:S50-4. Review.

PMID:
1707116
10.

Increased survival with beta-blockers: importance of ancillary properties.

Soriano JB, Hoes AW, Meems L, Grobbee DE.

Prog Cardiovasc Dis. 1997 Mar-Apr;39(5):445-56.

PMID:
9122425
11.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

12.

[Do beta-blockers prevent coronary events in hypertensive patients?].

Diévart F, Ragot S, Julien J, Herpin D.

Arch Mal Coeur Vaiss. 2005 Sep;98(9):881-8. Review. French.

PMID:
16231574
13.
14.

Beta-blocker underuse in secondary prevention of myocardial infarction.

Everly MJ, Heaton PC, Cluxton RJ Jr.

Ann Pharmacother. 2004 Feb;38(2):286-93. Epub 2003 Dec 30. Review.

PMID:
14742768
15.
16.

Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease.

Müller-Riemenschneider F, Damm K, Meinhard C, Bockelbrink A, Vauth C, Willich SN, Greiner W.

GMS Health Technol Assess. 2009 Dec 14;5:Doc16. doi: 10.3205/hta000078.

17.
18.

Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?

Hjalmarson A.

Basic Res Cardiol. 2000;95 Suppl 1:I41-5. Review.

PMID:
11192352
19.

Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis.

Bangalore S, Wild D, Parkar S, Kukin M, Messerli FH.

J Am Coll Cardiol. 2008 Sep 23;52(13):1062-72. doi: 10.1016/j.jacc.2008.05.057.

20.

Can antiarrhythmic drugs survive survival trials?

Pratt CM, Waldo AL, Camm AJ.

Am J Cardiol. 1998 Mar 19;81(6A):24D-34D. Review.

PMID:
9537220

Supplemental Content

Support Center